Abstract
Various administration routes of adeno-associated virus (AAV)-based gene therapy have been examined to target the central nervous system to answer the question what the most optimal delivery route is for treatment of the brain with certain indications. In this study, we evaluated AAV5 vector system for its capability to target the central nervous system via intrastriatal, intrathalamic or intracerebroventricular delivery routes in rats. AAV5 is an ideal candidate for gene therapy because of its relatively low level of existing neutralizing antibodies compared to other serotypes, and its broad tissue and cell tropism. Intrastriatal administration of AAV5-GFP resulted in centralized localized vector distribution and expression in the frontal part of the brain. Intrathalamic injection showed transduction and gradient expression from the rostral brain into lumbar spinal cord, while intracerebroventricular administration led to a more evenly, albeit relatively superficially distributed, transduction and expression throughout the central nervous system. To visualize the differences between localized and intra-cerebral spinal fluid administration routes, we compared intrastriatal to intracerebroventricular and intrathecal administration of AAV5-GFP. Together, our results demonstrate that for efficient transgene expression, various administration routes can be applied.
Highlights
Since the first clinical protocol was published for the treatment of Canavan’s disease (CD) in 2002 [1] great progress has been made in the field of adeno-associated virus (AAV) for neurological diseases
Presence of recombinant nucleic acids (DNA and RNA) was used to evaluate the capability of AAV5 to transduce the brain after parenchymal or cerebrospinal fluid (CSF)-mediated administration after AAV5 was administered to rats IStr, ICV, or ITH (Fig. 1)
We show that the distribution profile of AAV in the CNS is highly dependent on its delivery method
Summary
Since the first clinical protocol was published for the treatment of Canavan’s disease (CD) in 2002 [1] great progress has been made in the field of adeno-associated virus (AAV) for neurological diseases.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have